

# SPECIAL eBULLETIN

FOR PROFESSIONAL AND FACILITY PROVIDERS

SEPTEMBER 8, 2022

## \$0 COST-SHARE FOR MONKEYPOX DIAGNOSIS, TESTING AND VACCINE ADMINISTRATION

Following a recent [New York State \(NYS\) Executive Order](#), we're waiving copays, coinsurances, and deductibles for the diagnosis and testing of Monkeypox<sup>1</sup> as well as vaccine administration for your Highmark Blue Shield of Northeastern New York **fully-insured Commercial patients**.

Beginning August 28, 2022, through September 27 (or the end of the NYS Public Health Emergency) your Highmark BSNENY fully insured Commercial patients **will not** have to pay a cost-share for:

- Monkeypox vaccine administration from in- and out-of-network providers
- Diagnostic testing **from an in-network provider or laboratory** (HSA-qualified plans excluded)
- Office, urgent care, emergency department, outpatient, OR telehealth visits **with an in-network provider** to diagnosis Monkeypox<sup>2</sup> (HSA-qualified plans excluded)

Your office should not collect a cost-share for these patients.

For additional information on Monkeypox, please visit the NYS Department of Health and Centers for Disease Control and Prevention (CDC) websites below.

[NYS Department of Health](#)  
[CDC Monkeypox Information](#)

<sup>1</sup> HSA-qualified plans excluded from \$0 diagnosis and testing ONLY; cost-shares may be applied according to IRS regulations

<sup>2</sup> Cost-share may be imposed for any follow-up care or treatment for Monkeypox, including an inpatient hospital admission, in accordance with the patient's policy or contract

